As of 2024-12-15, the EV/EBITDA ratio of Arcturus Therapeutics Holdings Inc (ARCT) is -3.10. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARCT's latest enterprise value is 229.04 mil USD. ARCT's TTM EBITDA according to its financial statements is -73.87 mil USD. Dividing these 2 quantities gives us the above ARCT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.9x | 14.8x |
| Forward P/E multiples | 15.0x - 15.5x | 15.2x |
| Fair Price | (32.15) - (33.51) | (32.28) |
| Upside | -286.8% - -294.7% | -287.6% |
| Date | EV/EBITDA |
| 2024-12-13 | -3.10 |
| 2024-12-12 | -3.23 |
| 2024-12-11 | -3.37 |
| 2024-12-10 | -3.52 |
| 2024-12-09 | -3.69 |
| 2024-12-06 | -3.79 |
| 2024-12-05 | -3.34 |
| 2024-12-04 | -3.10 |
| 2024-12-03 | -3.35 |
| 2024-12-02 | -3.62 |
| 2024-11-29 | -3.51 |
| 2024-11-27 | -3.21 |
| 2024-11-26 | -3.00 |
| 2024-11-25 | -3.24 |
| 2024-11-22 | -2.99 |
| 2024-11-21 | -3.05 |
| 2024-11-20 | -2.72 |
| 2024-11-19 | -3.41 |
| 2024-11-18 | -2.76 |
| 2024-11-15 | -2.66 |
| 2024-11-14 | -3.51 |
| 2024-11-13 | -3.82 |
| 2024-11-12 | -3.97 |
| 2024-11-11 | -4.26 |
| 2024-11-08 | -3.99 |
| 2024-11-07 | -3.66 |
| 2024-11-06 | -3.51 |
| 2024-11-05 | -3.52 |
| 2024-11-04 | -3.32 |
| 2024-11-01 | -3.39 |
| 2024-10-31 | -3.29 |
| 2024-10-30 | -3.53 |
| 2024-10-29 | -3.80 |
| 2024-10-28 | -3.97 |
| 2024-10-25 | -3.74 |
| 2024-10-24 | -3.76 |
| 2024-10-23 | -4.12 |
| 2024-10-22 | -4.05 |
| 2024-10-21 | -4.45 |
| 2024-10-18 | -4.55 |
| 2024-10-17 | -4.34 |
| 2024-10-16 | -4.35 |
| 2024-10-15 | -4.48 |
| 2024-10-14 | -4.46 |
| 2024-10-11 | -4.66 |
| 2024-10-10 | -4.35 |
| 2024-10-09 | -4.82 |
| 2024-10-08 | -5.03 |
| 2024-10-07 | -5.54 |
| 2024-10-04 | -5.55 |